In This Article:
Healthpeak Properties, Inc. DOC is slated to report its fourth-quarter 2024 results on Feb. 3, after market close. While the quarterly results are expected to reflect year-over-year growth in revenues, funds from operations (FFO) per share might exhibit a decline.
See the Zacks Earnings Calendar to stay ahead of market-making news.
In the last reported quarter, this healthcare real estate investment trust (REIT) posted an FFO as adjusted per share of 45 cents, beating the Zacks Consensus Estimate by a penny. Results reflected better-than-anticipated revenues. Moreover, growth in total merger-combined same-store cash (adjusted) net operating income was witnessed across the portfolio.
In the preceding four quarters, Healthpeak’s FFO, as adjusted per share, surpassed the Zacks Consensus Estimate on all occasions, with the average beat being 2.26%. The graph below depicts this surprise history:
Healthpeak Properties, Inc. Price and EPS Surprise
Healthpeak Properties, Inc. price-eps-surprise | Healthpeak Properties, Inc. Quote
Factors at Play for Healthpeak
The increasing life expectancy of the U.S. population and biopharma drug development growth opportunities have promoted lab real estate market fundamentals. Healthpeak’s focus on the lab segment is a strategic fit and is expected to have been positively impacted by this tailwind, aiding revenue growth in the fourth quarter.
Moreover, the senior citizen population is on the rise, and the healthcare expenditure of this age cohort is usually on the higher end compared with the general population. Healthpeak’s continuing care retirement community portfolio, which refers to its retirement communities that include independent living, assisted living and skilled nursing units, is anticipated to have benefited from this positive expenditure trend, supporting the segment’s quarterly performance.
For the fourth quarter, the Zacks Consensus Estimate for DOC’s rental and related revenues currently stands at $544 million, implying growth of 31.9% from the prior-year period’s reported figure.
The Zacks Consensus Estimate for fourth-quarter total revenues is pegged at $689.2 million, indicating a rise of 24.5% from the year-ago reported number.
However, high interest expenses during the fourth quarter are likely to have been a spoilsport for Healthpeak.
Before the fourth-quarter earnings release, the company’s activities were inadequate to gain analysts’ confidence. The Zacks Consensus Estimate for the quarterly FFO per share has remained unchanged at 45 cents over the past three months. The figure suggests a 2.17% decrease from the year-ago quarter’s tally.